Genmab — Januar 2026
-
JP Morgan remains Neutral | Price Target Dkr 2,050 https://x.com/_ShahKruti/status/2013574730918527445
-
the whole trial went 'Active, not recruiting' already in june 23 and after the split both had the same Primary Completion date, Oct25, so we may not have to wait that long for the China part. Actually, maybe it is already included, it is a sub-study of DLBCL-1 ?
-
Føj......(-:
-
Der blev lidt tavst på chatten ! Er det Over and out, and RIP?
-
Man skulle da lige have taget lidt gevinsthjemtagning i 2250
-
...inden Trump-babyen gik i gang igen. "Kun" 3 år tilbage med hans rablende infantile vanvid xD
-
DNB Carnegie løfter Genmabs anbefaling til "køb" og skruer pænt op for kursmålet https://proinvestor.com/investornyt/1405261/dnb-carnegie-lofter-genmabs-anbefaling-til-kob-og-skruer-paent-op-for-kursmalet
-
hey gentogen , thinking again on that China part of the trial ; too many Asian patients in the trial was where Roche/Genentech got in trouble with Columvi wasn't it; they got a Complete Response Letter from the FDA for the reason that OS was much better in Asian patients compared to non-Asian patients so FDA determined OS was not proven for Americans
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind